FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

washington, D.C. 20049	

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

		Reporting Person* nces X, L.P.					me and Ticke OSCIENCE						ationship of k all applicat Director	ole)	Persor	10% Ov	vner
	K BIOSCIE	irst) NCES, INC. N STREET, SUI	(Middle) TE 300		3. Date 09/16/		arliest Transa 1	action (Mo	nth/D	ay/Year)			Officer (g below)	give title		Other (s below)	specify
(Street)	L IN	N	46032		4. If Am	endm	nent, Date of	Original I	Filed (Month/Day	/Year)	6. Ind		d by One	Report	Check Appling Person One Report	·
(City)	(S	tate)	(Zip)														
			Table I - Non					-	Dis								
1. Title of S	ecurity (Insti	r. 3)		2. Transac Date (Month/Da		Exe if a	Deemed ecution Date, ny onth/Day/Year	3. Transa Code (4. Securit Disposed	ies Acquire Of (D) (Ins	d (A) or r. 3, 4 and 5)	5. Amount Securities Beneficial Following		Form:	Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership
								Code	v	Amount	(A) ((D)	Price	Reported Transactio (Instr. 3 an	n(s) d 4)			(Instr. 4)
Common	Stock			09/16/2	2024			С		3,927,7	774 A	(1)	3,927	,774) (2)	
Common	Stock			09/16/2	2024			P		625,00	0 ⁽³⁾ A	\$16	4,552	,774]) (2)	
			Table II - [ities Acq warrants						wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code		Deri Sec Acq Disp	umber of ivative urities uired (A) or posed of (D) tr. 3, 4 and	6. Date I Expiration (Month/I	on Dat				8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici Owned Followin Reporte Transaci	ve es ally eg	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficia Ownersh (Instr. 4)
				Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Series A Convertible Preferred Stock	(1)	09/16/2024		С			18,922,852	(1)		(1)	Common Stock	1,574,005	(1)	0		D ⁽²⁾	
Series B Convertible Preferred	(1)	09/16/2024		С			28,297,265	(1)		(1)	Common Stock	2,353,769	(1)	0		D ⁽²⁾	

(Last)	(First)	(Middle)	
C/O MBX BIOS	SCIENCES, INC.		
11711 N. MERI	DIAN STREET, SU	JITE 300	
(Street)			
CARMEL	IN	46032	
(City)	(State)	(Zip)	
(Last)	(First)	(Middle)	
, ,	` ,	` ,	
— OUT UNION ST	REET, SUITE 3200		
(Street)			
	WA	98101	
SEATTLE			
SEATTLE (City)	(State)	(Zip)	
(City)	(State)		

(Last)	(First)	(Middle)
601 UNION ST	REET, SUITE 3200	
(Street)		
SEATTLE	WA	98101
(City)	(State)	(Zip)
	ess of Reporting Person	•
Topper Jame	<u>s N</u>	
Topper Jame (Last)	S N (First)	(Middle)
(Last)		, ,
(Last)	(First)	, ,
(Last) 601 UNION ST	(First)	, ,

Explanation of Responses:

- 1. Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.
- 2. These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. can be deemed to have beneficial ownership over such securities. Mr. Heron and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
- 3. Reflects shares purchased in the Issuer's initial public offering.

Frazier Life Sciences X, L.P., By: FHMLS X, L.P., its general partner, By: FHMLS X, L.L.C., 09/17/2024 its general partner, By: /s/ Steve R. Bailey, Chief Financial Officer FHMLS X, L.P., By: FHMLS X, L.L.C., its general partner, By: 09/17/2024 /s/ Steve R. Bailey, Chief Financial Officer FHMLS X, L.L.C., By: /s/ Steve R. Bailey, Chief Financial 09/17/2024 Officer /s/ Steve R. Bailey, Attorney-in-09/17/2024 Fact for James N. Topper ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.